The role of MicroRNAs in therapeutic resistance of malignant primary brain tumors

I Gareev, O Beylerli, Y Liang, H **ang, C Liu… - Frontiers in Cell and …, 2021‏ - frontiersin.org
Brain tumors in children and adults are challenging tumors to treat. Malignant primary brain
tumors (MPBTs) such as glioblastoma have very poor outcomes, emphasizing the need to …

Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment

L Dzialach, J Sobolewska, Z Zak… - Frontiers in …, 2024‏ - frontiersin.org
Prolactinomas (PRLomas) constitute approximately half of all pituitary adenomas and
approximately one-fifth of them are diagnosed in males. The clinical presentation of …

Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin …

R Cozzi, MR Ambrosio, R Attanasio… - European journal of …, 2022‏ - academic.oup.com
Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different
clinical settings and always require an individually tailored approach. This is the reason why …

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?

SMC De Sousa - Endocrine Oncology, 2022‏ - eo.bioscientifica.com
The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy
as the first-line treatment, with surgical resection reserved for cases where there is DA failure …

Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis

K Wright, L Chaker, D Pacione, K Sam, R Feelders… - World Neurosurgery, 2021‏ - Elsevier
Objective Prolactin-secreting tumors respond well to medical management, with a few
patients requiring surgery. We conducted a systematic review and meta-analysis to study the …

Functions of membrane progesterone receptors (mPRs, PAQRs) in nonreproductive tissues

P Thomas, Y Pang, MA Camilletti… - Endocrinology, 2022‏ - academic.oup.com
Gender differences in a wide variety of physiological parameters have implicated the
ovarian hormones, estrogens and progesterone, in the regulation of numerous …

Aggressive prolactinoma

A Valea, F Sandru, A Petca… - Experimental and …, 2022‏ - spandidos-publications.com
Aggressive prolactinoma (APRL) is a subgroup of aggressive pituitary tumors (accounting
for 10% of all hypophyseal neoplasia) which are defined by: invasion based on radiological …

Italian guidelines for the management of prolactinomas

R Cozzi, R Simona Auriemma… - … Metabolic & Immune …, 2023‏ - benthamdirect.com
Introduction: This guideline (GL) is aimed at providing a reference for the management of
prolactin (PRL)-secreting pituitary adenoma in adults. However, pregnancy is not …

Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas

EJ Medina, YM Zohdy, E Porto… - Frontiers in …, 2023‏ - frontiersin.org
Introduction Aggressive prolactinomas (APRLs) pose a significant clinical challenge due to
their high rate of regrowth and potentially life-threatening complications. In this study, we …

Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline

B Biagetti, S Sarria-Estrada… - European Journal of …, 2021‏ - academic.oup.com
Objective Transsphenoidal surgery (TSS) is mainly indicated in prolactinomas when
dopamine agonist treatment fails. However, there is no established early predictor of …